Purchase this article with an account.
Danielle Strauss, Gennady Landa, Patricia Garcia, Chirag Shah, Katy Tai, Melissa Rivas, Richard B Rosen; Improvement in microperimetry in patients receiving Copaxone for dry age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1127.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Copaxone (glatiramer acetate) has been previously shown to reduce drusen on SLO-OCT imaging in patients with dry age-related macular degeneration (AMD). This study compares retinal sensitivity using microperimetry in patients with dry AMD being treated with Copaxone versus placebo.
Eleven patients with dry AMD were enrolled in the study, 5 patients received weekly subcutaneous Copaxone injections, and 6 patients received sham treatment for a 12 week period. Patients were imaged with scanning laser ophthalmoscope microperimetry and optical coherence tomography (OPKO Health, Miami, FL). Microperimetry and macular topography was obtained at baseline and 6 weeks.
At 6-week follow-up, 9 (out of 10) eyes of patients treated with Copaxone demonstrated a mean 46.9% improvement in retinal sensitivity. Whereas 8 (out of 12) eyes of patients treated with placebo had a mean 6.2% decrease in light sensitivity. Effect of treatment was compared with effect of placebo using the one-tailed, independent 2-sample t-test, yielding a P=.071.
Patients with dry AMD being treated with Copaxone showed improvement of retinal sensitivity on Microperimetry at the 6 week follow-up. Patients receiving placebo showed stable or worse microperimetry over the course of 6 weeks.
This PDF is available to Subscribers Only